Risk of delays in biomarker discovery and clinical assay development
First written in FY2017. 2 of 4 entries say "Restated". Latest entry: FY2023.
Human Metabolome Technologies moved to the "Worse" side of this theme in 2023.
0 other companies' latest entry also says "Reframed".
- FY2023ReframedAnnual report
「Our group's growth is driven primarily by innovation through new development. Since failure is inherent in highly novel development, development may be abandoned because of insurmountable obstacles, or more obstacles than anticipated may arise that must be overcome to achieve the expected results, potentially lengthening the time required to achieve those results.」
The wording has been consolidated from specific risks of delays in discovery and test method development caused by insufficient patient samples or enzymes and antibodies to the broader risks of failure, obstacles and prolonged periods across new development in general. - FY2020RestatedAnnual report
「If the required number of biological samples from patients with the target disease cannot be collected, or if effective enzymes or antibodies cannot be obtained, the schedule through commercialisation may be delayed」
We continue to identify the risk of delays in biomarker discovery and clinical test method development caused by insufficient patient samples or failure to secure enzymes and antibodies. - FY2019RestatedAnnual report
「If the required number of biological samples from patients with the target disease cannot be collected, or if effective enzymes or antibodies cannot be obtained, the schedule through commercialisation may be delayed」
We continue to identify the risk of development delays caused by insufficient patient samples or failure to secure enzymes and antibodies. - FY2017First statedAnnual report
「If the required number of biological samples from patients with the target disease cannot be collected, or if effective enzymes or antibodies cannot be obtained, the schedule through commercialisation may be delayed, potentially affecting our group's business performance and future business development.」
The company identifies as a risk delays to the research and commercialisation schedule caused by insufficient patient samples or failure to obtain effective enzymes and antibodies.